New Report Covers Gamma Therapeutics, Inc. - Product Pipeline Analysis, 2016 Update
Gamma Therapeutics, Inc. - Product Pipeline Analysis, 2016 Update is a new market research publication announced by Reportstack. Gamma Therapeutics, Inc. (Gamma Therapeutics) is a biotechnology company which offers biopharmaceutical and diagnostic test solutions. The company’s product portfolio encompasses GammaCoeur, Gammarin and GammaSeal. GammaCoeur is developed to address the need for a new cardiovascular disease risk assay and complement traditional testing methods such as total fibrinogen, cholesterol for heart attack and stroke risk. Gammarin, a non-immunogenic, anticoagulant is a pharmaceutical drug that is being developed for use in patients undergoing major surgery. GammaSeal, a high strength surgical sealant is being developed for areas of mechanical strain such as wound repair or large artery vascular surgery. Its products are developed based on its technology, Gamma Prime Fibrinogen, which is a natural occurring protein in human blood. Gamma Therapeutics is headquartered in Portland, Oregon, the US.
To access full report with TOC, please visit Gamma Therapeutics, Inc. - Product Pipeline Analysis, 2016 Update
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Companies Mentioned
Dominion Diagnostics, LLC Castle Biosciences Incorporated Atherotech, Inc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 22:50
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home